Crown Electrokinetics
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / Crown Electrokinetics Corp. (NASDAQ:CRKN) ("Crown" or the "Company"), a prominent leader in smart glass technology and fiber optic network construction, today announced significant changes in its leadership team to bolster its capabilities further and accelerate to product launch.
Effective July 8, 2024, Tim Koch, who co-founded Crown Electrokinetics and has served as its Chief Technology Officer since 2015, will transition to the role of Chief Innovation Officer. As the new Chief Innovation Officer, Tim will focus on delivering electrokinetic film to the market and enhancing the company's product portfolio.
"We are excited to see Tim take on this new role. His leadership and technical expertise are invaluable as we strive to meet our clients' needs, deliver our electrokinetic film to market, and push the boundaries of what our technology can achieve," said Sheldon Davis, President.
Robert Vandal will assume the position of Chief Technology Officer starting July 8, 2024. With over three decades of experience in product development, process development, and manufacturing operations, Vandal has spearheaded pivotal advancements in the glass industry. He recently served as the Senior Director of R&D at Guardian Glass LLC, contributing significantly to key developments such as tempered vacuum insulating glass. His leadership has led to numerous successful global product launches across various areas of the glass industry. His extensive expertise will be instrumental in advancing our Dynamic Tint™ technology to market, developing our manufacturing capability, and accelerating the launch of Crown Smart Inserts.
"I am thrilled to welcome Rob to our team," remarked Tim Koch. "His leadership and knowledge will undoubtedly accelerate the delivery of our products to market. Rob's expertise will be crucial as we continue to build on our recent successes. We expect he will play a pivotal role in ensuring our offering not only meets but exceeds the expectations of our customers."
"I am incredibly excited to join Crown Electrokinetics at such a pivotal moment. The opportunity to bring innovations such as Dynamic Tint™ technology to market is exciting. I look forward to leveraging my experience to help propel Crown towards achieving future value-creating milestones."
Francois Prouhet is set to join as the Director of Business Development on July 8, 2024. In this role, Prouhet will utilize his experience to develop Crown's go-to-market strategy, establish business partnerships, and provide support for day-to-day execution. He has previously held positions at Guardian Industries and Cars.com, where he gained expertise in decision support analytics, financial modeling, and developing go-to-market strategies.
Sheldon Davis added, "Having Francois and Rob on our team marks a significant step. Their diverse experience and mindsets are crucial as we accelerate our development and product launch."
In connection with new appointments and pursuant to the agreed-upon terms, Crown granted Mr. Vandal 6,667 RSU and Mr. Prouhet 2,334 RSU as an inducement equity award outside of Crown's 2022 Employee Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The vesting dates will be based on business milestones agreed to between employees and the Compensation Committee of the Board of Directors for Crown. These inducement awards were approved by Crown's Board of Directors (the "Board"), including a majority of the independent directors serving on the Board.
About Crown Electrokinetics
Crown is comprised of two divisions, Fiber Optics and Electrokinetics Film. The Electrokinetics Film division is a smart glass technology and the creator of our Smart Window Insert based on its patented electrokinetic film. Crown's Fiber Optics division is a builder of underground fiber optic networks as well as other utility infrastructure projects.
Safe Harbor Statement:
Statements in this news release may be "forward-looking statements". Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Crown Electrokinetic Corporation undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Crown Electrokinetics Contact:
IR Email: info@crownek.com
SOURCE: Crown Electrokinetics
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds Across the Americas15.7.2025 16:45:00 CEST | Press release
Following GEON's acquisition of Foster, LLC, this new agreement expands Formerra's healthcare polymer portfolio with life-saving medical compounds. ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America. The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our cust
FairWinds Migrates from .COM to .FAIRWINDS, Showcasing Leadership in Strategic Internet Addressing15.7.2025 16:00:00 CEST | Press release
WASHINGTON, DC / ACCESS Newswire / July 15, 2025 / FairWinds Partners, the world's leading domain name strategy consultancy, has completed the migration of its website from fairwindspartners.com to home.fairwinds. "This transition is more than a domain change. It reflects our belief in the future of .BRAND top-level domains," said FairWinds founder Josh Bourne. "Our move to .FAIRWINDS reinforces the strategic value that these top-level domains offer and our evolution from a pioneering domain name advisory firm to the trusted partner for global brands navigating the digital landscape via the address bar." Unlike second-level domains like google.com, top-level domains reside on the internet's root servers -- the foundation of the internet's naming system. .BRAND top-level domains are not publicly available and are used exclusively by the brand owner. ".BRAND top-level domains provide a powerful way to amplify, control, and secure a brand's digital presence while giving visitors visual pr
QorusDocs Reports 360% Increase in Customers Using AI to Manage Proposals, Acquires Shark Finesse to Build Unified AI-Powered Value and Proposal Platform15.7.2025 13:00:00 CEST | Press release
BELLEVUE, WA / ACCESS Newswire / July 15, 2025 / QorusDocs, an AI-powered proposal management software company that streamlines creation of pitches, proposals and request for proposal (RFP) responses, today announced that its customers' use of AI to manage proposals has grown 360% year over year, and that it has acquired Shark Finesse Ltd, a United Kingdom-based AI-powered customer value management software. "AI is completely transforming how business development teams win business, and QorusDocs is at the forefront," said Ray Meiring, CEO of QorusDocs. "The majority of our customers now rely on AI to manage proposals. We're at a pivotal moment, and with the acquisition of Shark Finesse, we're poised to deliver on companies' full revenue enablement journey, from proving value to winning the deal." QorusDocs Acquires Shark Finesse With Shark Finesse joining QorusDocs, the company's vision is to enable business development and proposal teams to prove value early in the revenue cycle, wit
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease15.7.2025 09:50:00 CEST | Press release
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce Partnership Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-
IXOPAY Surges Past 500 Certified Adapters, Solidifies Leadership in Enterprise-Grade Payment Orchestration15.7.2025 06:00:00 CEST | Press release
With 200 PSPs and 300 payment methods, IXOPAY is unlocking faster global expansion, improved approval rates, and full-stack control for enterprise merchants. LEHI, UT / ACCESS Newswire / July 15, 2025 / As global commerce accelerates, enterprise merchants are hitting a wall - their legacy payment stacks weren't built for the scale, complexity, or speed modern commerce demands. To stay competitive, merchants need infrastructure that adapts across markets, providers, and payment methods without costly rewrites or vendor lock-in. IXOPAY, a global leader in enterprise-grade payment orchestration, is addressing that challenge head-on with the announcement it has reached 500 certified adapters, connecting 200 payment service providers (PSPs) and 300 payment methods through a single, vendor-agnostic API. Payment orchestration is rapidly emerging as vital infrastructure for modern payments, and its effectiveness depends on the scale and breadth of the adapter ecosystem. IXOPAY's industry-leadi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom